share_log

Novartis AG Says Novartis Cosentyx Gains Positive CHMP Opinion For Hidradenitis Suppurativa; Opinion Paves Way For First New Treatment Option In Hidradenitis Suppurativa In Nearly A Decade; Regulatory Decision From U.S. FDA Expected Later This Year

Novartis AG Says Novartis Cosentyx Gains Positive CHMP Opinion For Hidradenitis Suppurativa; Opinion Paves Way For First New Treatment Option In Hidradenitis Suppurativa In Nearly A Decade; Regulatory Decision From U.S. FDA Expected Later This Year

诺华股份公司表示，Novartis Cosentyx获得CHMP对化脓性汗腺炎的积极看法；意见为近十年来化脓性汗腺炎的首个新治疗选择铺平了道路；美国食品药品管理局预计将于今年晚些时候做出监管决定
Benzinga ·  2023/04/27 23:15

Novartis AG Says Novartis Cosentyx Gains Positive CHMP Opinion For Hidradenitis Suppurativa; Opinion Paves Way For First New Treatment Option In Hidradenitis Suppurativa In Nearly A Decade; Regulatory Decision From U.S. FDA Expected Later This Year

诺华股份公司表示，Novartis Cosentyx获得CHMP对化脓性汗腺炎的积极看法；意见为近十年来化脓性汗腺炎的首个新治疗选择铺平了道路；美国食品药品管理局预计将于今年晚些时候做出监管决定

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发